Wet Age Related Macular Degeneration Market Global Analysis 2017 Wet Age Related Macular Degeneration Market | Page 3

Wet Age Related Macular Degeneration Industry: Global Trend, Profit, and
Key Manufacturers Analysis Report
There are two types of AMD: Dry and Wet. About 90 per cent of AMD cases are classified as dry AMD.
Usually, AMD starts as a dry type and can develop in one or both eyes. The process is slow and can advance
over the course of several years. About 10 percent of all cases of Age-related Macular Degeneration
become “Wet” AMD. It is a condition in which new blood vessels grow in the choroid layer behind the
retina.
For wet AMD treatment, anti-vascular endothelial growth factor (anti-VEGF) is generally used which may
halt or delay the progression of visual loss. By blocking the action of VEGF chemical, it helps prevent the
condition from progressing and may partially reverse it. Anti-VEGF medicines include Eylea, Lucentis and
Avastin. However, treatment in most people maintains vision and prevents the condition from becoming
worse.
The report “Global Wet AMD market: Industry Analysis & Outlook (2017-2021)” analyses the
development of this market, with focus on the U.S. and outside the U.S. markets. The major trends, growth
drivers as well as issues being faced by the market are discussed in detail in this report. The four major
players: Regeneron Pharmaceuticals, Inc. Novartis International AG, Roche Holding AG & Bayer Group are
being profiled along with their key financials and strategies for growth. The report contains a
comprehensive analysis of the global wet AMD market along with the study of the regional markets.
Purchase a Copy of This Report at
http://www.marketreportsonline.com/contacts/purchase.php?name=584683